NCT03614299

Brief Summary

The objective of this observational study is to develop new tools to assess primary Sjögren's syndrome (pSS) symptoms and to measure the severity of eye involvement in these patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
45

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2019

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 31, 2018

Completed
3 days until next milestone

First Posted

Study publicly available on registry

August 3, 2018

Completed
1.3 years until next milestone

Study Start

First participant enrolled

November 20, 2019

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 28, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 28, 2020

Completed
Last Updated

February 5, 2025

Status Verified

February 1, 2025

Enrollment Period

9 months

First QC Date

July 31, 2018

Last Update Submit

February 3, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Variability in the intensity of patient-reported symptoms

    Variability over time (day-to-day assessment) of the ESSPRI score (dispersion of the values compared to the mean)

    3 months

Secondary Outcomes (3)

  • Tolerability of the daily use of a webapp to measure the symptoms

    Month 3

  • Interferometry

    3 months

  • Automated eye surface coloration measurement

    3 months

Study Arms (1)

pSS cohort

Patients with pSS included in the study

Other: Ecological symptom measurements using a webappDiagnostic Test: Interferometry

Interventions

A webapp will be installed on the patients' smartphone, which will be used to collect everyday the symptoms of the patients (ESSPRI score)

pSS cohort
InterferometryDIAGNOSTIC_TEST

Evaluation of the mebomian function using the LipiView methodology

pSS cohort

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Consecutive pSS patients seen in Rheumatology

You may qualify if:

  • diagnosis of pSS according to ACR/EULAR classification criteria

You may not qualify if:

  • patient does not possess a smartphone with web connection
  • patient unable to sign an informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU de BREST

Brest, 29200, France

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum, saliva, cells

MeSH Terms

Interventions

Microscopy, Interference

Intervention Hierarchy (Ancestors)

MicroscopyDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisInterferometryInvestigative Techniques

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 31, 2018

First Posted

August 3, 2018

Study Start

November 20, 2019

Primary Completion

August 28, 2020

Study Completion

August 28, 2020

Last Updated

February 5, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will share

All collected data that underlie results in a publication

Shared Documents
STUDY PROTOCOL
Time Frame
Data will be available beginning after publication of result and ending three years maximum following the last visit of last patient
Access Criteria
Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.

Locations